What's Happening?
LEO Pharma has announced the appointment of Sophie Lamle as the new Executive Vice President of Development, effective December 1, 2025. Lamle, who previously led the global R&D innovative medicines team
at Teva Pharmaceuticals, will join LEO Pharma's Global Leadership Team. Her role will focus on strengthening the company's Search & Development innovation model, which aims to unlock value through differentiated assets. Lamle brings over 20 years of experience in the pharmaceutical industry, with a background in driving innovation, clinical development, and strategic transformation. Her appointment is expected to bolster LEO Pharma's efforts in medical dermatology, a field in which the company is a global leader.
Why It's Important?
The appointment of Sophie Lamle is significant for LEO Pharma as it seeks to enhance its leadership in medical dermatology. With her extensive experience in the pharmaceutical industry, Lamle is well-positioned to drive innovation and strategic partnerships that could lead to the development of new treatments for skin diseases. This move is likely to strengthen LEO Pharma's competitive position in the dermatology market, potentially benefiting millions of patients worldwide. The focus on differentiated clinical programs aligns with the company's commitment to making a fundamental difference in people's lives through innovative skin health solutions.
What's Next?
Sophie Lamle will officially assume her role on December 1, 2025, succeeding Mark Levick, who will continue to serve on the Board of Directors and as Chair of the Innovation Committee. As Lamle integrates into her new position, LEO Pharma is expected to continue its focus on innovation and strategic growth in the dermatology sector. The company's ongoing efforts to develop breakthrough medicines and expand its portfolio could lead to new partnerships and advancements in skin health treatments.
